Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

ABSTRACT:

Importance

Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.

Objective

To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.

Design, setting, and participants

Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites.

Interventions

The GLP-1 agoni

SUBMITTER: Margulies KB 

PROVIDER: S-EPMC5021525 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature